British Columbia Cancer Agency clinical trials
Listed in the registry as: University, hospital or other organization.
The registry lists 152 studies whose lead sponsor is British Columbia Cancer Agency. 33 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 19, 2026.
Keep track of what changes. Save the British Columbia Cancer Agency studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesStatus
Focus areas
Conditions British Columbia Cancer Agency leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 50 of 152. Browse all 152 →
- CSF Analysis in EGFR Mutant Non-Small Cell Lung Cancer With Leptomeningeal DiseaseRecruitingNCT05257967Not applicable
- Evidence Development in Cancer Treatment - Real World: PREDiCTrwRecruitingNCT06242912Not applicable
- PRecision Oncology Evidence Development in Cancer Treatment - Clinical: PREDiCTcRecruitingNCT04814095Not applicable
- CLIC-2201 for the Treatment of Relapsed/Refractory B Cell MalignanciesRecruitingNCT06208735Phase 1
- Radiotherapy 12Gy in 6 Fractions For Orbital LymphomaNot yet recruitingNCT07210749Not applicable
- A Comparison of [68Ga]DOTATATE and [18F]AmBF3TATE for the Staging and Assessment of Neuroendocrine MalignanciesNot yet recruitingNCT07621146
- Preliminary Assessment of [18F]BL40 in PET/CT ScansRecruitingNCT06224309
- Using Tumour DNA and Proteins to Better Understand How Pancreatic Cancer Responds to TreatmentRecruitingNCT06574620Not applicable
- Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible SensitivityRecruitingNCT04273061Phase 2
- Using Strength Tests to Better Understand How Pancreatic Cancer Affects Muscle Mass and Quality of LifeRecruitingNCT07255001Not applicable
- Monitoring and Managing Glucose Levels in People With Pancreatic CancerRecruitingNCT05132244Not applicable
- Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic AnalysisRecruitingNCT02869802
- Single vs Hypofractionated Irradiation For Timely Access to Partial Breast RadiotherapyRecruitingNCT06885671Not applicable
- High Dose Radiotherapy for Palliation (Hi-D)Not yet recruitingNCT07291895Not applicable
- Partial Prostate Salvage High Dose Rate BrachytherapyRecruitingNCT03246802Not applicable
- Phase II Randomized Trial of 2 Versus 5 Fraction Prostate Stereotactic Ablative Radiotherapy for Intermediate Risk Prostate CancerRecruitingNCT06835725Phase 2
- 5500/20 vs. SABR or Brachytherapy for PRimary OligoMetastatic Prostate Cancer Treatment (PROMPT)RecruitingNCT04610372Not applicable
- STRatIfication of Vulvar Squamous Cell Carcinoma by HPV and p53 Status to Guide ExcisionRecruitingNCT05576831Not applicable
- Multi-omic Approach to Study HDR Brachytherapy for Favorable Risk and Low Tier Intermediate Risk Prostate CancerRecruitingNCT06200974
- 177Lu-HTK03170 in mCRPC With PSMA Positive DiseaseEnrolling by invitationNCT05570994Phase 1/2
- Stereotactic Radiotherapy Versus Palliative Conventional Radiotherapy for Oligoprogressive Metastatic CancersRecruitingNCT06918951Not applicable
- Personalized Oncogenomics (POG) Program of British ColumbiaRecruitingNCT02155621Not applicable
- Genomic and Transcriptomic Predictors of Sequential SG Sensitivity After T-DXd in ER+/HER2-Low Metastatic Breast CancerRecruitingNCT06665178Phase 2
- Time Restricted Eating in Haematological MalignanciesNot yet recruitingNCT06862323Phase 2
- SABR PRIMER - Evaluating Stereotactic Ablative Radiotherapy for Primary and Regional Breast TumorsNot yet recruitingNCT06937281Not applicable
- DOTATATE PET for Meningioma Radiation PlanningNot yet recruitingNCT06937268Not applicable
- NEoadjuvant Olaparib Combination OvArian Cancer Targeted StudyNot yet recruitingNCT06650709Phase 2
- Improving Detection of Early Lung Cancer in a Diverse Population (IDEAL) StudyRecruitingNCT06628102Not applicable
- 13C-Glucose Tracing of Tumour and T Cells in the Ascites of Ovarian Cancer Patients.RecruitingNCT05025878
- A Comparison of 2 Standard Doses of Bevacizumab in Combination With Chemotherapy in Epithelial Ovarian CancerRecruitingNCT04787289Phase 2
- Diagnostic CT Palliative Radiotherapy: Feasibility Study of Treating Bone Metastases Without a CT SimulationNot yet recruitingNCT06235034Not applicable
- Optimizing Prostate Cancer Treatment in Men With Advanced Local DiseaseRecruitingNCT03836196Not applicable
- PATH Trial: Personalized Approaches in the Treatment of Head and Neck CancerNot yet recruitingNCT05373251Not applicable
- PRecision Oncology Evidence Development in Cancer Treatment - LiquidActive, not recruitingNCT05057234Not applicable
- Efficacy Study of Switching to a Lutenizing Hormone-releasing Hormone (LHRH) Antagonist From a LHRH Agonist to Treat Progressive Castrate Resistant Prostate Cancer (CRPC)WithdrawnNCT01630967Phase 2
- Stereotactic Ablative Body Radiotherapy (SABR) for OligometastasesActive, not recruitingNCT02933242Not applicable
- HELP Study - Towards High Throughput and Efficient Long-axial PET With Oral [18F]FDGActive, not recruitingNCT07295171Not applicable
- RAPid SimPLE Targeted Radiation Treatment for Brain MetastasesActive, not recruitingNCT05050929Phase 2
- Comparison of HDR vs. LDR Brachytherapy as Monotherapy for Intermediate Risk Prostate CancerActive, not recruitingNCT02692105Phase 3
- DOTATOC PET/CT for Imaging NET PatientsActive, not recruitingNCT03583528
- Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic (1-3 Metastases) CancerActive, not recruitingNCT03862911Not applicable
- SUPR-3D: Simple Unplanned Palliative Radiotherapy Versus 3D Conformal Radiotherapy for Patients With Bone MetastasesTerminatedNCT03694015Not applicable
- Partial Breast Irradiation Using Interstitial Permanent Palladium-103 Seed ImplantActive, not recruitingNCT02297672Not applicable
- LDR vs. HDR Brachytherapy for Prostate CancerActive, not recruitingNCT03426748Not applicable
- Improving Quality of Life After Prostate Brachytherapy: a Comparison of HDR and LDR BrachytherapyActive, not recruitingNCT01936883Not applicable
- PROstate Cancer TReatment Optimization Via Analysis of Circulating Tumour DNAActive, not recruitingNCT04015622Phase 2
- [68Ga]Ga-PSMA-11 PET/CT in the Assessment of High Risk and Recurrent Prostate CancerActive, not recruitingNCT04484701
- Dynamic Whole Body PET/ MRIWithdrawnNCT04495959
- PSMA PET/CT for Assessment of Recurrent Prostate CancerActive, not recruitingNCT02899312
- Study of Osimertinib + SRS vs Osimertinib Alone for Brain Metastases in EGFR Positive Patients With NSCLCActive, not recruitingNCT03769103Phase 2